Strongbridge Biopharma plc(SBBP)stock report

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Market Cap:148.5M; Shares Outstanding:54.2M; Short Interest: 1.14%; Q3 2019(9/30/19): Cash 79.61M. Loss 13.79M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 0.69 122.19% 160.53%
2019.3.31 -0.34 48.48% -149.28%
2019.6.30 -0.49 28.99% -44.12%
2019.9.30 -0.75 34.21% -53.06%


Date Sales % last year % last quarter
2018.12.31 18.03M 155.85% 33.46%
2019.3.31 4.34M 12.22% -75.93%
2019.6.30 10.42M 27.63% 140.09%
2019.9.30 16.11M 19.19 54.61%


Insider Transactions:

Institution Ownership:

Total institutions: 66,no change
Shares hold: 27345.1k shares. no change
shares% hold: 50.45%,no change

Analyst Ratings:

Leave a Reply